image
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
Aelis Farma announces the recruitment of the first patient for the phase 1/2 clinical trial of its drug candidate AEF0217 for the treatment of cognitive diso...
December 2022
+
Aelis Farma announces positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndro...
November 2022
+